Application of circ-SLC38A1 as target point in medicine for inhibiting bladder cancer cells

A technology of bladder cancer and drugs, applied in the field of tumor biological gene therapy, can solve the problems of bleeding and infection risks, low sensitivity, and low sensitivity of carcinoma in situ diagnosis
CN112011620AActive Publication Date: 2020-12-01THE SECOND HOSPITAL OF SHANDONG UNIV
6 Cites 3 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
THE SECOND HOSPITAL OF SHANDONG UNIV
Publication Date
2020-12-01

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention belongs to the technical field of tumor biological gene therapy, and relates to a bladder cancer diagnosis and treatment biomarker and a target spot, in particular to application of circ-SLC38A1 as a target spot in a bladder cancer cell inhibition medicine. The invention discloses an expression condition of circ-SLC38A1 in tumor tissues of a bladder cancer patient and a function of circ-SLC38A1 in bladder cancer cells. It is found for the first time that circ-SLC38A1 can be used as a bladder cancer diagnosis biomarker and a drug therapy target. Compared with normal control, circ-SLC38A1 is significantly up-regulated in tumor tissues of bladder cancer patients. The result of the invention shows that interference on circ-SLC38A1 can inhibit the migration and invasion ability ofbladder cancer cells, and it is shown that the circ-SLC38A1 plays a role of a cancer-promoting gene in the occurrence and development of bladder cancer, and provides a new target for clinical treatment of bladder cancer.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of tumor biological gene therapy, and relates to a biological marker and a target for diagnosis and treatment of bladder cancer, in particular to the application of circ-SLC38A1 as a target in drugs for inhibiting bladder cancer cells. Background technique

[0002] Bladder cancer (BC) is the most common malignant tumor of the urinary system and one of the ten most common tumors in the whole body. It accounts for the first place in the incidence of urogenital tumors in my country, and ranks second in the West after prostate cancer. In 2012, the incidence rate of bladder cancer in the national tumor registration area was 6.61 / 100,000, ranking ninth in the incidence rate of malignant tumors. Bladder cancer can occur at any age, even in children, and the incidence and mortality of cancer have continued to rise in recent decades. About 25% of urothelial carcinomas are diagnosed as muscle-invasive bladder cancer...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More